NCCN Guidelines for Patients® Version Updates: Ovarian Cancer

Following are the major updates that were included in the NCCN Guidelines for Patients®: Ovarian Cancer, Version 1.2015.

  • Part 1 – Ovarian cancer basics
  • Page 6 – Table of contents
    • Changes have been made to the titles, topics, and organization of sections in this chapter
  • Page 8 – “Types of ovarian cancer” is new to this chapter
  • Page 9 – “Borderline ovarian cancer” is now referred to as “ovarian LMP (low malignant potential) tumor” throughout this patient guideline

Part 2 – Testing for ovarian cancer

  • Page 14 – Table of contents
    • This chapter is now organized into sections based on  the types of tests
  • Page 14 – General health tests
    •  “Genetic counseling and testing” is a new recommendation in this section
  • Page 16 – Imaging tests
    •  “Chest x-ray” is new to this section

Part 3 – Cancer staging

  • Page 26 – Ovarian cancer stages
    • The cancer stages have been updated to reflect the new FIGO staging classifications  

Part 4 – Overview of cancer treatments

  • Page 35 – Chemotherapy
    • Added one new chemotherapy regimen: paclitaxel and carboplatin (weekly)
  • Page 37 – Targeted therapy
    • Added two new drug options: olaparib and pazopanib

Part 5 – Treatment guide

  • Page 44 – Table of contents
    • The treatment recommendations are now organized into the following sections:
      • Ovarian LMP (low malignant potential) tumor,
      • Stage I ovarian cancer,
      • Stage II, III, and IV ovarian cancer, and
      • Follow-up after initial treatment
  • Page 60 – Chart 5.3.4 Chemotherapy regimens for stage II, III, and IV ovarian cancer
    • Added one new chemotherapy regimen: paclitaxel and carboplatin (weekly)
  • Page 62 – Chart 5.3.5 Treatment after primary chemotherapy
    • Under “Treatment options” for a complete response:
      • Added one new option: “Maintenance treatment with pazopanib”
    • Under “Treatment options” for a partial response:
      • The third option is now “Best supportive care” instead of “Start follow-up”
  • Page 66 – Chart 5.4.2 Treatment for ovarian cancer that has come back
    • Under “Treatment options” for a clinical or radiographic relapse <6 months after finishing chemotherapy:
      • The third option is now “Best supportive care” instead of “Start follow-up”
  • Page 68 – Chart 5.4.3 Recurrence treatment
    • Under “Preferred options” for “Platinum-sensitive disease”:
      • Added one new option: olaparib
    • Under “Preferred options” for “Platinum-resistant disease”:
      • Added four new options: liposomal doxorubicin/bevacizumab; olaparib; paclitaxel (weekly)/bevacizumab; and topotecan/bevacizumab
    • Under “Other options”:
      • Added one new option: doxorubicin